This Technical Report accompanies the Clinical practice guidelines for keratinocyte cancer, developed by Cancer Council Australia.
It outlines the guideline development process and methodology, lists the clinical questions, provides all accompanying NHMRC Statement Forms, the detailed technical documentation for each question and the risk of bias assessment tools used to assess the included literature as a result of a systematic review.
Evidence statement forms, systematic review reports and modelling reports
The following reports are for questions that were answered by a new systematic literature review or modelling. The associated technical documentation appears at the bottom of the relevant content pages.
The questions were given alphanumeric codes when they were developed, please refer to the codes below and see the Clinical question list for more detail.
SX1: What factors need to be considered when determining if surgical treatment modalities are optimal over non-surgical modalities for the management and/or treatment of basal cell carcinoma or cutaneous squamous cell carcinoma?
Evidence statement form SX1
Systematic review report SX1
SX3: In patients undergoing surgical treatment for cutaneous squamous cell carcinoma, which surgery-related factors (margin width, depth of excision) or tumour-related factors (size, histological features, anatomical site) influence clinical outcomes (cure rate, local recurrence, regional lymph node involvement, metastasis)?
Evidence statement form SX3
Systematic review report SX3
RT3: In which patients with cutaneous squamous cell carcinoma does a radiotherapy modality achieve equal or better outcomes than conventional surgery?
Evidence statement form RT3
Systematic review report RT3
OT1: What role does ingenol mebutate gel have in the treatment and management of basal cell carcinoma and/or cutaneous squamous cell carcinoma?
Evidence statement form OT1
Systematic review report OT1